| 29.58 -0.09 (-0.3%) | 05-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 35.35  |
1-year : | 37.84 |
| Resists | First : | 30.27 |
Second : | 32.4 |
| Pivot price | 28.42 |
|||
| Supports | First : | 26.82 |
Second : | 22.32 |
| MAs | MA(5) : | 29.08 |
MA(20) : | 28.9 |
| MA(100) : | 35.21 |
MA(250) : | 29.99 |
|
| MACD | MACD : | -0.7 |
Signal : | -1 |
| %K %D | K(14,3) : | 65.4 |
D(3) : | 55.1 |
| RSI | RSI(14): 50 |
|||
| 52-week | High : | 45.58 | Low : | 17.53 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ IMVT ] has closed below upper band by 8.9%. Bollinger Bands are 53.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 29.71 - 29.86 | 29.86 - 29.96 |
| Low: | 28.51 - 28.71 | 28.71 - 28.84 |
| Close: | 29.29 - 29.6 | 29.6 - 29.79 |
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Tue, 07 May 2024
Immunovant (IMVT) Reports Wider-Than-Expected Loss in Q2 - Yahoo Canada Shine On
Tue, 07 May 2024
Federated Hermes Inc. Lowers Stock Holdings in Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Tue, 07 May 2024
Why Is Immunovant, Inc. (IMVT) Up 13.9% Since Last Earnings Report? - Yahoo Canada Shine On
Mon, 06 May 2024
Reasons to Add Immunovant (IMVT) Stock to Your Portfolio Now - Yahoo Movies Canada
Sat, 04 May 2024
Zurcher Kantonalbank Zurich Cantonalbank Acquires 951 Shares of Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Fri, 26 Apr 2024
This Insider Has Just Sold Shares In Immunovant - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 145 (M) |
| Shares Float | 64 (M) |
| Held by Insiders | 55.5 (%) |
| Held by Institutions | 47.4 (%) |
| Shares Short | 8,510 (K) |
| Shares Short P.Month | 9,350 (K) |
| EPS | -1.81 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.67 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -27.2 % |
| Return on Equity (ttm) | -44.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.75 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -210 (M) |
| Levered Free Cash Flow | -126 (M) |
| PE Ratio | -16.35 |
| PEG Ratio | -4.5 |
| Price to Book value | 6.32 |
| Price to Sales | 0 |
| Price to Cash Flow | -20.44 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|